INTRODUCTION
Cell cycle control is a fundamental process that governs cell proliferation and is frequently altered during tumorigenesis. E2Fs and their heterodimer partners, DPs, are central regulators of cell cycle progression and directly regulate the expression of a broad spectrum of genes involved for instance, in cell cycle regulation, DNA replication and repair, apoptosis, differentiation or development , .
[1 2 ]
E2F1, which was discovered as a protein promoting the transition to S phase, was the founding member of the E2F family which comprises eight members in mammals. Among this family, some were initially presented as activator E2Fs (E2F1, 2, and 3) while the " "
other members were mostly known as transcription repressors although this classification now appeared too simplistic ( and reference [2 ] herein). E2F transcriptional activity was shown to be regulated by a large number of coactivators or corepressors including the so-called pocket proteins which form the retinoblastoma (RB) tumor suppressor family (pRB, together with the related proteins p107 and p130) . [3 ] RB attenuates E2F action by recruiting transcriptional corepressors such as histone deacetylases (HDACs) to E2F-regulated promoters, thus mediating transcriptional repression of E2F-regulated genes , . RB is a critical component of the cell cycle control machinery [4 5 ] and, as a consequence, its loss or inactivation is a major mechanism by which cancer cells attain a growth advantage during tumorigenesis . [6 ] Our laboratory is engaged in the characterization of various transcriptional repressors which regulate another important class of transcription factors, namely nuclear hormone receptors. These receptors such as the estrogen and androgen receptors are also important RIP140 controls E2F1 activity Clin Cancer Res . Author manuscript Page / 2 12 regulators of cell proliferation and strongly influence the growth of hormone-dependent cancers . These receptors control gene [7 ] expression through the recruitment of a large set of coregulatory proteins which regulate, either positively or negatively, chromatin structure and transcription initiation. Our work is mainly focused on RIP140 (Receptor Interacting Protein of 140 kDa also known as NRIP1), a nuclear protein of 1158 amino acids, initially identified as a transcription cofactor of estrogen receptors and shown to regulate energy homeostasis in metabolic tissues (for a review see ). RIP140 is an atypical coregulator since, despite its recruitment by [8 ] agonist-liganded nuclear receptors, it exhibits a strong transcriptional repressive activity. We and others have deciphered the molecular mechanisms involved in this transrepression and identified four repressive domains within the RIP140 molecule . We also [9 ] [10 ] demonstrated that RIP140 expression was increased upon estrogen or androgen stimulation, in breast and prostate cancer cells, [11 ] [ 12 ] respectively.
The present study identified RIP140 as a novel transcriptional repressor of E2F1 activity which significantly decreased E2F1-target gene expression both on transfected reporter constructs and on endogenous genes. In human breast cancers, a decrease in RIP140 expression is inversely correlated with E2F1-target gene expression and significantly associated with basal-like tumors which exhibit bad prognosis. Altogether this work identifies RIP140 as a new key actor of the E2F pathway and as a potential new prognostic marker in oncology.
MATERIALS AND METHODS

Plasmids and reagents
The E2F1 and DP1 expression vectors were given by Dr C. Sardet (IGMM, Montpellier, France), the E2F ( . The 17M5 Glob-Luc construct and plasmids allowing RIP140 expression , , have been described previously. The 13 ] β [9 11 12 ] pEGFP-C2-RIP140 vector was a kind gift of Dr J. Zilliacus . The deletion of the E2F interaction domain in the RIP140 sequence [14 ] (from residues 119 to 199) was done using the QuickChange XL from Stratagene. The pRL-CMVbis plasmid (Ozyme, Saint Quentin Yvelines, France) was used to normalize transfection efficiency.
Cell culture, RNA extraction and quantitative PCR
HeLa, MCF-7 and HEK293T human cancer cell lines were cultured as previously described . Total RNA was extracted from cells [9 ] using the TRIzol reagent (Invitrogen, Cergy Pontoise, France). Total RNA (2 g) was subjected to a reverse-transcription step using the μ Superscript II reverse transcriptase (Invitrogen). Real-time quantitative polymerase chain reaction was performed using a SYBR Green approach (LightCycler, Roche Diagnostics, Meylan, France). Primer sequences are available upon request. For each sample, results were corrected for RS9 mRNA levels (reference gene) and were normalized to a calibrator sample.
Transient transfection, luciferase assays and cell cycle analysis
MCF-7 cells were plated in 96-well plates (2.10 cells per well) 24h prior to DNA transfection with Jet-PEI (0.25 g of total DNA). interaction assay and coimmunoprecipitation In vitro translation and GST pull-down assays were performed as previously described . For coimmunoprecipitations, expression In vitro [9 ] plasmids for E2F1 or c-myc-tagged RIP140 were transfected in HeLa cells using JetPEI (Ozyme, Saint Quentin Yvelines, France). After cell lysis in 50 mM Tris-HCl, pH8, 0.5 Nonidet P-40 supplemented with protease inhibitors, Transfected RIP140 and E2F1 were % immunoprecipitated with the 9E10 monoclonal antibodies against the c-myc epitope or with the anti-E2F1 antibody (C-20) covalently bound to protein G-Sepharose beads. After incubation at 4 C during 2 h and 5 washes, immunoprecipitated proteins were eluted in°L aemmli sample buffer, resolved by SDS PAGE and detected by western blotting using primary antibodies against E2F or c-myc epitope.
-
Interaction of endogenous proteins (coimmunoprecipitation and ChIP analysis)
For coimmunoprecipitation of endogenous proteins, 700 g of MCF-7 cell nuclear extracts (prepared using the NE-PER kit from μ Thermo Scientific) were incubated with 2 g of anti-E2F1 monoclonal antibody (KH95 sc-251 Santa Cruz) for 3 hours at room μ temperature. Beads coupled to Protein G (Ademtech G0433) were added to the immune complex (2 hrs at room temperature) and after 3 washes with lysis buffer, beads were resuspended in 20 l of lysis buffer and analysed by western blotting using primary antibodies μ specific for E2F1 (KH95 sc-251 Santa Cruz) and RIP140 2656C6a (sc-81370 Santa Cruz). For ChIP analysis, MCF-7 cells (70% confluent) were synchronized using 4mM hydroxyurea (HU) during 24h and the block was released by changing the medium with 10% FCS supplementation for the indicated time. After PBS washing and cross-linking with 3, 7 formaldehyde during 10 min at 37 C, we used the ChampionChIP One-Day Kit (SABiosciences) according to the manufacturer s recommendations and using either the antibody ' KH95 (sc-251 SantaCruz) or 2656C6a (sc-81370 Santa-Cruz) for E2F1 and RIP140 respectively, or no antibody as a control. Q-PCR was then performed using the Power SYBR Green PCR master mix (Applied Biosystems) on an Applied Biosystems 7300 thermal cycler with 
Microarray analysis
Microarray data (accession number GSE1992) of the study from Hu et al. were obtained from the Gene Expression Omnibus [15 ] (GEO) database ( ). Expression data from the 170 sample experiment were downloaded as http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi normalised and log2 transformed Cy5/Cy3 ratios, where tumor sample RNA and human universal reference RNA were labeled with Cy5 and Cy3, respectively. Hierarchical pairwise average-linkage clustering of the 170 tumor specimens was performed on the basis of expression of RIP140 and 6 E2F1-target genes using the Cluster and TreeView software with median-centered gene expression values and Pearson correlation as similarity metrics. Results were analyzed for statistical significance using the 2-tailed Student s test. For all ' t analyses, < 0.05 was considered as significant. p
RESULTS
RIP140 interacts with E2F1
Based on published data reporting that nuclear receptor coregulators were involved in the regulation of E2F1 activity , we [16 -18 ] hypothesized that RIP140 might also act as a transcriptional modulator of the E2F pathway.
Using GST pull-down assays, we first investigated whether RIP140 was able to interact with E2F1. We therefore performed in vitro pull-down assays with GST-E2F1 and labeled full-length RIP140. As shown in (left panel), data clearly demonstrated in vitro Figure 1B the binding of RIP140 to E2F1. We then tried to delineate the respective binding sites on the two proteins. The use of deletion mutants of E2F1 and RIP140 corresponding to the N-terminal or the C-terminal moiety of the two proteins (fused to GST for E2F1 and in vitro translated for RIP140) suggested the presence of at least two interaction domains on each protein ( right panel). Indeed, the two Figure 1B translated fragments of RIP140 (fragment 1 to 480 and 480 to 1158) were retained by the GST-E2F1 chimaeric proteins in vitro encompassing regions from residues 1 to 123 or 123 to 437.
In order to further map the respective binding sites on RIP140, we used deletion mutants of RIP140 fused to GST. Data shown in (left panel) indicated that the N-terminal region of RIP140 encompassing residues 27 to 439 exhibited the strongest binding of Figure 1C translated full-length E2F1. No binding at all was observed with the central region of RIP140 whereas a faint interaction was in vitro detectable upon long exposure with the C-terminal region (residues 683 to 1158). This E2F1 binding region was clearly confirmed when we used the translated fragment of E2F1 corresponding to residues 1 to 123 ( , left panel). in vitro Figure 1C Moreover, using a series of deletion mutants in the N-and C-terminal moieties of RIP140, we showed that the minimal N-terminal E2F1 interaction domain (EID1) encompassed a region of 80 amino acids spanning from residues 119 to 199 whereas EID2 was mapped to a region spanning from residues 916 to 1158 ( and , right panel). Finally, an E2F1 mutant lacking the Figure 1A Figure 1C
transactivation domain which encompasses residues 380 437 was significantly less efficient (more than 7-fold decrease) than wild-type -E2F1. This region corresponds to the pRB interaction domain which is strongly impaired by the Y411H mutation . Very interestingly, [19 ] this Y411H E2F1 mutant was also less efficient to interact with RIP140 ( ), suggesting that the C-terminal RIP140 binding site Figure 1D on E2F1 might overlap that of pRB.
To demonstrate that this interaction between RIP140 and E2F1 also occurred in intact cells, we then set up co-immunoprecipitation experiments. As illustrated in (top panel), RIP140 was found associated with immunoprecipitated E2F1 and the reverse Figure 2A experiment confirmed the interaction between the two proteins (bottom panel). All controls performed with the sole expression of one partner, or with the use of beads alone confirmed the specificity of the interactions. In order to emphasize these results, we then analyzed the association between endogenous proteins in MCF7 breast cancer cells. Coimmunoprecipitation experiments demonstrated that E2F1 was able to specifically pull-down endogenous RIP140 ( ). Finally, chromatin immunoprecipitation (ChIP) analysis was Figure 2B performed in MCF-7 cells on E2F binding sites in the cyclin D1 promoter which is transcriptionally repressed by E2F1
. Data [20 ] indicated a concomitant increase in E2F1 and RIP140 recruitment upon G1/S transition ( ). Altogether, these results illustrated Figure 2C the interaction between endogenous RIP140 and E2F1, and binding of RIP140 on an E2F1 target promoter, thus strengthening the data presented in . Figure 1 
RIP140 inhibits E2F1 transactivation
We next tested the ability of RIP140 to control E2F1 transactivation in transient transfection experiments using expression vectors for both E2F1 and DP1, together with different luciferase reporter vectors known to be regulated by E2Fs. We first used an artificial reporter RIP140 controls E2F1 activity Clin Cancer Res . Author manuscript Page / 4 12 plasmid containing three copies of the E2F binding site upstream the thymidine kinase promoter (E2F -TK-Luc). As shown in 3 Figure 3A (left panel), when transfected in MCF-7 breast cancer cells, we observed a significant inhibition of E2F1 activity upon overexpression of RIP140. Similar inhibition of E2F1 transactivation by RIP140 (ranging from 4-to 8-fold) was obtained on two other reporter constructs corresponding to the natural cyclin E or ARF promoters ( , middle and right panels, respectively) and, as shown in , Figure 3A Figure 3B
the cyclin E promoter was dose-dependently repressed by RIP140. Moreover, the same repressive effect of RIP140 on E2F1 was observed upon transient transfection of other human cancer cell lines such as HeLa or HEK293T (data not shown) and was not restricted to E2F1.
Indeed, we found that the two other activator E2Fs E2F2 and E2F3 not only interacted with RIP140 but were similarly i.e. in vitro inhibited upon RIP140 overexpression (see supplementary Figure S2 ).
In order to further characterize the mechanism of this inhibitory effect, we used plasmids allowing the expression of Gal4-E2F1 chimeric proteins fusing the DNA-binding domain of the Gal4 yeast transcription factor to the COOH-terminal moiety of E2F1 (amino acids 123 to 437 or 380 to 437 which both contain the transactivation domain). In these conditions, we obtained a similar dose-dependent transcriptional repression upon RIP140 overexpression ( ), suggesting that this effect was not due to a regulation of the binding Figure 3C of E2F1 to DNA or to its heterodimerization partners (DP proteins). Finally, we compared, the effect of RIP140 to that of the pocket protein pRB, and found that, in our experimental conditions, E2F1 activity on the cyclin E promoter was repressed to comparable levels although the residual transactivation by E2F1 (compared to basal level) was higher with RIP140 than with pRB ( left panel). On Figure 3D the Gal-E2F1(380 437) chimaeric protein, the effect of RIP140 was slightly less efficient than that of pRB probably reflecting the loss of -the N-terminal binding site for RIP140 (see above). Altogether, these results demonstrated that RIP140 was able to interact with E2F1 and to repress its transcriptional activity.
RIP140 decreases cell cycle progression and regulates E2F-target gene expression
Having demonstrated that RIP140 was a novel repressor of E2F1 activity, we sought to directly address whether this regulation might impact cell proliferation. We first examined the effect of RIP140 overexpression on cell cycle distribution in various human cancer cell lines. HeLa cells were transfected with a GFP-RIP140 expression vector and two populations overexpressing (GFP-RIP ) or not (GFP-RIP + ) RIP140 were separated and analyzed for cell cycle distribution by FACS. 
+
Since the data shown in suggested that the NH2-terminal EID1 (residues 119 to 199) was the strongest binding site for Figure 1 in translated full-length E2F1, we generated the corresponding RIP140 mutant ( EID1 deleted from amino acids 119 to 199) as a fusion vitro Δ with GFP. In transient transfection experiments, we found that this EID1 mutant was significantly less efficient (p<0.01) to repress Δ E2F1/DP1 transactivation on the cyclin E promoter ( ). This effect was specific of E2F transactivation since wild-type RIP140 Figure 4B and the EID1 deletion mutant inhibited estrogen receptor transcriptional activity to the same extend (data not shown). We also analyzed Δ the effect of the EID1 mutant on cell cycle ( ). We found that its overexpression in MCF7cells led to an increase in the Δ Figure 4C proportion of cells in G1 (as compared to GFP alone) and this increase was significantly lower (p<0.01) than that obtained with the wildtype GFP-RIP40 vector. These results thus indicated that deletion of the main E2F1 interacting domain significantly impaired RIP140 ability to repress E2F transactivation and to block cell cycle progression.
In an attempt to explain the growth effect associated with RIP140 expression, we then analyzed by quantitative RT PCR, the steady-state levels of various mRNAs known to be transcribed from E2F-target genes . As shown in , we first noticed that in [4 ] Figure 4D
cells overexpressing the GFP-RIP140 expression vector, the mRNA levels of CCNE, CCNB2, CDC2 and CDC6 were strongly decreased as compared to cells which did not overexpressed GFPRIP140. The negative regulation was however not general for all E2F-traget genes since for instance, the DHFR mRNA levels were not significantly regulated ( ). Altogether, these results indicated that RIP140 Figure 4C controls cell cycle progression and regulates endogenous E2F-target gene expression.
Inverse correlation between RIP140 and E2F1-target genes in human breast cancers
To determine the biological relevance of E2F control by RIP140 and to validate the regulation by RIP140 of some of the E2F1-target genes in human cancers, we analyzed the expression of RIP140 and E2F1-target genes on a tumor microarray data set representing 170 breast cancer patients . We first selected among 16 known E2F1-target genes shown to be related to tumor proliferation, those [15 ] presenting the most pronounced differential expression in tumors with low levels of RIP140 tumors with high levels of RIP140 (the two vs groups including tumors with log2 RIP140 expression values lower and upper than 0, respectively). As shown in , six genes ( Figure 5A and ) which presented the most important and significant differences in expression ratio CCNE1, MYBL2, BIRC5, E2F1, CCNB2 CDC6 RIP140 controls E2F1 activity Clin Cancer Res . Author manuscript Page / 5 12 between tumors with low and high RIP140 mRNA levels were selected for clustering analysis. It should be noted that three of these genes and were found regulated by RIP140 in MCF-7 cells ( ). i.e. CCNE1, CDC6 CCNB2 Figure 4C The gene expression signature comprising RIP140 and the 6 selected E2F1-target genes was used to cluster the 170-point data set and is displayed as a condition tree in . This map clearly showed two regions of gene coregulation, low levels of RIP140 mRNA Figure 5B being associated with high levels of the E2F1-target genes whereas in tumors expressing high levels of RIP140 mRNA, the E2F1-target genes were underexpressed. As shown in , the mean expression levels of the six E2F1-target genes were significantly lower (p Figure 5C epithelial cells) and associated with significant differences in clinical outcome . Using the tumor microarray data set from Hu [21 ] et al. [15 , we investigated how RIP140 could discriminate between these molecular subtypes and whether the regulation of E2F1-target genes by ] RIP140 could be observed in these distinct subclasses. We anticipated that it could be the case since a proliferation gene cluster including E2F1-target genes has been shown to be differentially expressed through the breast tumor subtypes and reported as a hallmark of a [15 ] series of prognosis molecular signatures , ;
. The 170 tumors were ranked according to RIP140 gene expression and divided [22 23 ] [24 ] into two equal groups of 85 tumors with low and high RIP140 expression levels, respectively. As expected, the E2F1-target metagene expression almost mirrored the RIP140 mRNA levels in these two tumor groups ( ). Interestingly, as shown in , the Figure 6A Altogether, these data suggested that, in breast cancers, low RIP140 mRNA expression was associated with high E2F1-target gene levels and basal-like tumors.
DISCUSSION
RIP140 was initially identified as a transcriptional repressor of ligand-activated nuclear hormone receptor, involved in the control of ovarian functions and metabolic pathways (for a review, see ). In the present study, we identified RIP140 as a novel transcriptional [25 ] repressor of E2F1 and as a new important regulator of cell proliferation. Based on both protein-protein interaction assays, in vitro coimmunoprecipitation and ChIP experiments, our data clearly demonstrate that RIP140 is an E2F1 partner. Transcriptional repression of E2F1 activity by RIP140 was observed in transient transfections on various E2F-target promoters and strong inverse correlations between RIP140 and E2F-target genes were noted upon overexpression of RIP140 in breast cancer cells. More interestingly, the same observation ( low levels of RIP140 associated with high expression of E2F1 targets) was made using data obtained on a set of 170 human breast i.e. cancer samples.
Other nuclear receptor cofactors were previously reported as E2F regulators. However, most of these studies dealt with transcriptional activators such as CBP , PCAF or more recently ASC-2/NCOA6 or AIB1/NCOA3 . RIP140, acting as a negative [26 ] [16 ] [17 ] [18 ]
regulator of E2F1, thus appears to act similarly to the well-known pocket proteins although no structural similarities could be detected [3 ] between RIP140 and pRB, p107 or p130. It has been shown that pocket proteins exhibit some specificity towards E2F family members.
Indeed, pRB targets preferentially the activator E2Fs (E2F1, 2 and 3), whereas p107 and p130 are involved in the regulation of E2F4 and E2F5 . We are currently trying to determine whether RIP140 exhibits a similar specificity amongst E2F transcription factors and our [1 ] preliminary results indicate that RIP140 is not specific for E2F1, E2F2 and E2F3 and also interacts with repressor E2Fs ( Figure S2 ).
RIP140 controls E2F1 activity
Clin Cancer Res . Author manuscript Page / 6 12 Very interestingly, our data also identified RIP140 as a new regulator of cell proliferation with a significant impact on cell cycle progression since transient overexpression of RIP140 significantly decreased the number of cells in S phase. The function of RIP140 in cell proliferation was supported by the observation that DNA synthesis (assessed by incorporation of 5-ethynyl-2 -deoxyuridine) was ′ significantly increased in tissues from RIP140 knock-out mice as compared to wild-type littermates (M. Lapierre, unpublished data). [27 ] Moreover, in addition to their roles on cell cycle and cell proliferation, E2F1 and/or RB are also key players in the control of major biological processes such as apoptosis or differentiation and deregulation of this pathway is of major relevance in tumorigenesis , .
[1 3 ] Experiments are therefore currently in progress in our laboratory to evaluate the relevance of RIP140 on the control of these parameters and more globally to determine whether RIP140 loss has a direct impact on cancer formation. Based on the data published on pocket proteins, this might not be obvious since, although mice are prone to develop pituitary and thyroid tumors , no increase in RB / − + [28 ] tumor formation upon p107 or p130 gene invalidation was observed, except in an background . In addition, several studies RB / − + [3 ] [29 ] have reported that deregulation of the E2F signaling pathway could be linked to antiestrogen resistance in breast cancers . It will be [30 ] therefore very important to investigate whether RIP140, through its effects on E2F signaling, could be involved in resistance of mammary tumors to antiestrogen therapy. markers for predicting relapse in breast cancer. Interestingly, when we analyzed published transcriptomic data obtained on human breast tumors , we clearly demonstrated that RIP140 mRNA levels discriminate between the different cancer subtypes classified as basal-or [15 ] luminal-like based on the basis of molecular profiling. Our results indicate that low RIP140 mRNA levels correlate with basal-like tumors whereas those expressing high levels of RIP140 mRNA are mostly luminal-like (see and S1). Figure 6 These data therefore suggest that RIP140 may help to improve molecular signatures used to classify breast cancers. However, further work is needed to assess the association of RIP140 expression with clinical outcome and to determine the relative contribution of this gene as compared to the different markers previously identified. domains (EID) mapped on RIP140.
GST pull-down assays were carried out as (B and C) interaction between RIP140 and E2F1. In vitro described in using GST or GST-E2F1 with S-labelled wild-type RIP140 (B) or GST-RIP140 mutant proteins to retain Material and Methods
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S-labelled wild-type E2F1 (C) Inputs represent 25 of the material used in the assays.
GST pull-down assays carried out with the
GST-RIP(27 439) construct and S-labelled wild-type or mutants E2F1.
Figure 2
Interaction between RIP140 and E2F1 in intact cells HeLa cells were either transfected with pCDNA3-E2F1 (lanes 4 6) or (A) Co-immunoprecipitation of RIP140 and E2F1. 
Figure 5
Inverse correlation between RIP140 and E2F1-target gene expression in breast cancer The 170 samples from (A) Differential statistical analyses between 2 groups of tumor specimens defined by RIP140 expression values. the Hu study were separated into two groups according to their RIP140 expression levels. Fifty-five (low RIP140 expression) and et al [15 ] 115 (high RIP140 expression) tumors exhibited log 2-transformed RIP140 expression values lower and upper than 0, respectively. The median expression of each of 16 E2F1-target genes was determined within each of the 2 groups and the ratios of the respective median values were calculated.
. . The expression value of the E2F1-target metagene was defined in each tumor metagene into the 2 groups defined by RIP140 expression as the mean expression of the 6 E2F1-target genes selected in (A). RIP140 and metagene expression values were visualised for the low and high RIP140 tumor groups using boxplots.
Figure 6
RIP140 expression discriminates luminal and basal breast cancer subtypes
The 170 breast tumors of the study from Hu (A) E2F1-target metagene expression in the low and high RIP140 expression tumor groups. et al.
were ranked according to RIP140 gene expression and divided into two equal groups (85 tumors) exhibiting low and high RIP140 [15 ] expression, respectively. Expression values for RIP140 and E2F1-target metagene (defined as the mean expression of the 6 E2F1-target genes selected in ) are expressed as means SE and -values (Student s test) are indicated. 
